Business
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX)
About this update from Dogwood Therapeutics, Inc.
[{"type":"image","alt":"Dogwood Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dogwood Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5oqVaVpm5SX3iW1kYFN9Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300}},"lazy":false},{"type":"text","content":"- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID -","length":167,"tagName":"p"},{"type":"text","content":"- Dogwood Granted a Tiered Royalty up to 15% on Net Sales -","length":59,"tagName":"p"},{"type":"text","content":"- Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 -","length":177,"tagName":"p"},{"type":"text","content":"ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood’s anti-viral candidates, IMC-1 and IMC-2. The agreement includes potential payments of up to $100 million to Dogwood and its current and former shareholders.","length":628,"tagName":"p"},{"type":"text","content":"Dogwood Therapeutics previously announced its intention to explore partnership opportunities to advance its combination antiviral drug candidates and shift its primary focus to advancing its NaV 1.7 inhibitor, Halneuron®, to treat both chronic and acute pain conditions. Dogwood subsequentially in-licensed SP16, administered via intravenous formulation, as a complement to its lead asset Halneuron®, further deepening the Company’s focus on developing new treatments for chemotherapy induced pain and neuropathy.","length":513,"tagName":"p"},{"type":"text","content":"Consistent ...